
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2025



S

SENATE BILL DRS15184-MG-96

	Short Title:	Fair Pricing & Trnspncy/340B Covered Entities.(Pub	olic)					
	Sponsors:	Senators Galey, Burgin, and Sawrey (Primary Sponsors).						
	Referred to:							
1		A BILL TO BE ENTITLED						
2	AN ACT EST	FABLISHING FAIR PRICING AND TRANSPARENCY REQUIREMENTS F	OR					
3	340B COVERED ENTITIES.							
4	The General Assembly of North Carolina enacts:							
5	SECTION 1.(a) Chapter 131E of the General Statutes is amended by adding a new							
6	Article to read	d:						
7		"Article 11C.						
8		" <u>340B Covered Entities.</u>						
9		"Part 1. Fair Pricing of 340B Drugs by Hospitals.						
10		50. Definitions.						
11		wing definitions apply in this Part:						
12	(1		<u>: 42</u>					
13		<u>U.S.C. § 256b(b)(2).</u>						
14	<u>(2</u>							
15		42 U.S.C. § 256b and 42 C.F.R. Part 10, as both are from time to the	ime					
16		amended.						
17	<u>(3</u>		<u> 10B</u>					
18		drug.	10					
19	<u>(4</u>		<u>42</u>					
20		<u>U.S.C. § 256b(a)(4)(M).</u>						
21		.52. Fair pricing of 340B drugs by hospitals.						
22		d entity that acquires a 340B drug for a discounted price under the 340B Progr						
23		shall not accept an amount greater than the acquisition cost for the 340B drug as payment for						
24		dministering, or otherwise delivering the 340B drug to a patient.						
25		54. Violations constitute unfair or deceptive trade practice.	f					
26 27		ation of this Part constitutes an unfair or deceptive trade practice in violation and is subject to all of the enforcement and penalty provisions of an unfair						
27			<u> </u>					
28 29	deceptive trac	de practice under Article 1 of Chapter 75 of the General Statutes. "Part 2. 340B Covered Entity Transparency.						
29 30	"8 131F 7 1/	.60. Definitions.						
31		wing definitions apply in this Part:						
32	<u>1110 101104</u> (1		for					
33	<u>(1</u>	reduced prices by a manufacturer pursuant to 42 U.S.C. § 256b, and						
34		purchased by a covered entity.	* 10					
35	<u>(2</u>		or a					
36	<u>\</u> 2	covered outpatient drug pursuant to 42 U.S.C. § 256b.	<u> </u>					



General As	semb	ly Of I	North Carolina	Session 2025
	(3)	340B	Program. – The federal 340B Drug Pricing Program	authorized under
-	<u> </u>	-	S.C. § 256b and 42 C.F.R. Part 10, as both are from	
		amen		
((4)	Chari	ty care The costs reported on Form CMS-2552-10,	Worksheet S-10,
		Line	23 or any successor form.	
<u>(</u>	(5)	Cove	red entity A covered entity, as defined in 42 U.S.C.	<u>§ 256b(a)(4).</u>
<u>(</u>	(6)	Cove	red outpatient drug. – A covered outpatient drug, as def	ined in 42 U.S.C.
		<u>§ 139</u>	<u>6r-8(k)(2).</u>	
" <u>§ 131E-21</u>	4.62.	Annu	al reporting requirements.	
			October 1, each covered entity shall report to the Depart	
			the Department, the following information regarding	
			vered entity and each offsite outpatient facility, clinic	c, eligible offsite
location, or	other		sociated with the covered entity:	
<u>(</u>	(1)		eated by form of insurance or payor type, including, b	out not limited to,
		Medi	caid, Medicare, commercial insurance, and uninsured:	
		<u>a.</u>	Aggregate acquisition cost paid for all 340B drugs.	
		<u>b.</u>	Aggregate payments received by individuals, insure	
			all 340B drugs. For the purpose of this sub-subdiv	vision, aggregate
			payments include cost-sharing amounts.	
		<u>c.</u>	The total number of prescriptions and what percenta	ge of the covered
			entity's prescriptions were filled with 340B drugs.	
<u>(</u>	(2)	Attes	tation as to whether the covered entity did any of the fo	
		<u>a.</u>	Passed on 340B Program discounts to patients of the	•
			the form of lower cost-sharing for 340B drugs	at the point of
			dispensing or administration.	
		<u>b.</u>	Provided a sliding fee scale for 340B drugs for patie	
			income is less than two hundred percent (200%) of the	e federal poverty
			level established pursuant to 42 U.S.C. § 9902.	
<u>(</u>	<u>(3)</u>		operating costs of the covered entity, including itemize	ed costs, for each
		of the	following:	
		<u>a.</u>	Implementation of the policies described in subdiv	vision (2) of this
			subsection, if applicable.	
		<u>b.</u>	Charity care.	
<u>(</u>	<u>(4)</u>		payments made by the covered entity or any agent of t	he covered entity
		to any	v of the following:	
		<u>a.</u>	Any pharmacies under contract with the covered e	
			340B drugs for 340B program-related services and o	
		<u>b.</u>	Third-party administrators, including pharmacy bene	
			managing any components of the covered entity's pa	articipation in the
			<u>340B Program.</u>	
		<u>c.</u>	Any other third parties in connection with 340B	
			compliance, legal, educational, or administrative cos	
<u>(</u>	(5)		number of pharmacies under contract with the covered	entity to dispense
		<u>340B</u>	drugs, and among those, the following information:	
		<u>a.</u>	The number of pharmacies located out-of-state and the	ne states in which
			the out-of-state pharmacies are located.	
		<u>b.</u>	Total number of prescriptions and orders for 340B d	
			covered entity and by each offsite outpatient facility	
			the covered entity, and the percentage of such prescr	•
			that were filled at such pharmacies, delineated	by in-State and
			out-of-state pharmacies.	

	General Assembly Of	Session 2025			
1	<u>C.</u>	Total remuneration paid to or retained by such ph	narmacies or their		
2		affiliates for any 340B program-related services per	rformed on behalf		
3		of the covered entity and each offsite outpatient f	facility associated		
4		with the covered entity.			
5	<u>d.</u>	The percentage change in remuneration described i	n sub-subdivision		
5		(4)c. of this subsection for the preceding calendar	year compared to		
7		the year before that.			
8	(b) An officer of the covered entity shall certify to the completeness and accuracy of the				
9	report submitted pursuant to subsection (a) of this section.				
0	" <u>§ 131E-214.64. Postir</u>				
1	The Department shall make all the reports received by covered entities pursuant to				
2		able to the public on the Department's internet website			
3		I.(b) Part 1 of Article 11C of Chapter 131E of the Ge			
ŀ	•	applies to any covered drug, as defined by 42 U.S.C.			
5	-	ed, or otherwise delivered to a patient by a covered en	-		
5	date this act becomes law. As used in this subsection, the term "covered entity" has the same				
7	meaning as in G.S. 1311				
3		L.(c) Covered entities subject to Part 2 of Article 11C	1		
)		s, as enacted by this section, shall submit the first	report due under		
)	G.S. 131E-214.62 by O				
_	SECTION 2	2. This act is effective when it becomes law.			